Discussion
NGN-401, an experimental gene therapy for Rett syndrome, acts quickly in the nervous system to increase levels of the critical protein MeCP2, which is missing or defective in patients, according to new preclinical data. The therapy, developed by Neurogene, is currently in late-stage clinical trials. “We found that NGN-401’s…